Sepsis syndromes: Understanding the role of innate and acquired immunity

Shock

Volumn 16, Issue 2, 2001, Pages 83-96

  Oberholzer, Andreas ^a   Oberholzer, Caroline ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; CARS; Immunosuppression; MARS; Pro and anti inflammatory cytokine; Sepsis; SIRS

Indexed keywords

BIOLOGICAL MODEL; HUMAN; IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; IMMUNITY; IMMUNITY, NATURAL; MODELS, IMMUNOLOGICAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0035434019     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200116020-00001     Document Type: Review

References (160)

1. Wheeler AP, Bernard GR: Treating patients with severe sepsis. N Engl J Med 340:207-214, 1999.
2. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993.
3. Stone R: Search for sepsis drugs goes on despite past failures. Science 264: 365-367, 1994.
4. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113: 227-242, 1990.
5. Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25:556-566, 1999.
6. Bone RC: Sepsis and controlled clinical trials: the odyssey continues. Crit Care Med 23:1313-1315, 1995.
7. Baue AE: Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome. Why no magic bullets? Arch Surg 132:703-707, 1997.
8. Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095-1100, 1997.
9. Fry DE: Sepsis syndrome. Am Surg 66:126-132, 2000.
10. Tsagarakis S, Grossman A: Corticotropin-releasing hormone: interactions with the immune system. Neuroimmunomodulation 1:329-334, 1994.
11. Elenkov IJ, Chrousos GP: Stress, cytokine patterns and susceptibility to disease. Baillieres Best Pract Res Clin Endocrinol Metab 13:583-595, 1999.
12. Bucala R: MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J 10:1607-1613, 1996.
13. Brown E, Atkinson JP, Fearon DT: Innate immunity: 50 ways to kill a microbe. Curr Opin Immunol 6:73-74, 1994.
14. Ezekowitz RAB, Hoffmann JA: Innate immunity. Curr Opin Immunol 8:1-2, 1996.
15. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 272:50-53, 1996.
16. Oberholzer A, Oberholzer C, Moldawer LL: Cytokine signaling - regulation of the immune response in normal and critically ill states. Crit Care Med 28:N3-N12, 2000.
17. Beutler B: Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12:20-26, 2000.
18. O'Neill LA, Dinarello CA: The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today 21:206-209, 2000.
19. Anderson KV: Toll signaling pathways in the innate immune response. Curr Opin Immunol 12:13-19, 2000.
20. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, Brennan PJ, Bloom BR, Godowski PJ, Modlin RL: Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732-736, 1999.
21. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ: Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 274:17406-17409, 1999.
22. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D: Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 163:1-5, 1999.
23. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088, 1998.
24. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 189:615-625, 1999.
25. Tobias PS, Soldau K, Ulevitch RJ: Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 164:777-793, 1986.
26. Ulevitch RJ, Tobias PS: Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13:437-457, 1995.
27. Akashi S, Ogata H, Kirikae F, Kirikae T, Kawasaki K, Nishijima M, Shimazu R, Nagai Y, Fukudome K, Kimoto M, Miyake K: Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2. Biochem Biophys Res Commun 268:172-177, 2000.
28. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 93:2879-2883, 1996.
29. Schnare M, Holtdagger AC, Takeda K, Akira S, Medzhitov R: Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 10:1139-1142, 2000.
30. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454, 1999.
31. Janeway CA: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13:11-16, 1992.
32. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045, 1994.
33. Bendelac A, Fearon DT: Innate pathways that control acquired immunity. Curr Opin Immunol 9:1-3, 1997.
34. Gallucci S, Lolkema M, Matzinger P: Natural adjuvants: endogenous activators of dendritic cells. Nat Med 5:1249-1255, 1999.
35. Biron CA: Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 6:530-538, 1994.
36. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173, 1989.
37. Aral KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T: Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59: 783-836, 1990.
38. + T cell responses: the alternative approaches. Annu Rev Immunol 15:297-322, 1997.
39. Tomlinson S: Complement defense mechanisms. Curr Opin Immunol 5:83-89, 1993.
40. Liszewski MK, Post TW, Atkinson JP: Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 9:431-455, 1991.
41. Frank MM, Fries LF: The role of complement in inflammation and phagocytosis. Immunol Today 12:322-326, 1991.
42. Bhakdi S, Tranum-Jensen J: Complement lysis: a hole is a hole. Immunol Today 12:318-321, 1991.
43. Kreutz M, Ackermann U, Hauschildt S, Krause SW, Riedel D, Bessler W, Andreesen R: A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes. Immunology 92:396-401, 1997.
44. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754, 1991.
45. Rosenbach T, Czarnetzki BM: Comparison of the generation in vitro of chemotactically active LTB4 and its omega-metabolites by human neutrophils and lymphocytes/monocytes. Clin Exp Immunol 69:221-228, 1987.
46. Miyamoto K, Lange M, McKinley G, Stavropoulos C, Moriya S, Matsumoto H. Inada Y: Effects of sho-saiko-to on production of prostaglandin E2 (PGE2), leukotriene B4 (LTB4) and superoxide from peripheral monocytes and polymorphonuclear cells isolated from HIV infected individuals. Am J Chin Med 24:1-10, 1996.
47. Simoni J, Simoni G, Lox CD, McGunegle DE, Feola M: Cytokines and PAF release from human monocytes and macrophages: effect of hemoglobin and contaminants. Artif Cells Blood Substit Immobil Biotechnol 22:525-534, 1994.
48. Camussi G, Aglietta M, Coda R, Bussolino F, Piacibello W, Tetta C: Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology 42:191-199, 1981.
49. Dugas B, Mossalayi MD, Damais C, Kolb JP: Nitric oxide production by human monocytes: evidence for a role of CD23. Immunol Today 16:574-580, 1995.
50. Taub DD: Chemokine-leukocyte interactions: the voodoo that they do so well. Cytokine Growth Factor Rev 7:355-376, 1996.
51. Ward SG, Bacon K, Westwick J: Chemokines and T lymphocytes: more than an attraction. Immunity 9:1-11, 1998.
52. Nelson PJ, Krensky AM: Chemokines, lymphocytes and viruses: what goes around, comes around. Curr Opin Immunol 10:265-270, 1998.
53. Downey GP: Mechanisms of leukocyte motility and chemotaxis. Curr Opin Immunol 6:113-124, 1994.
54. Ribeiro RA, Flores CA, Cunha FQ, Ferreira SH: IL-8 causes in vivo neutrophil migration by a cell-dependent mechanism. Immunology 73:472-477, 1991.
55. Leonard EJ, Skeel A, Yoshimura T, Rankin J: Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes. Adv Exp Med Biol 351:55-164, 1993.
56. Engelhardt E, Toksoy A, Goebeler M, Debus S, Brocker EB, Gillitzer R: Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol 153:1849-1860, 1998.
57. Antony VB, Godbey SW, Kunkel SL, Hott JW, Hartman DL, Burdick MD, Strieter RM: Recruitment of inflammatory cells to the pleural space: chemotactic Cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 151:7216-7223, 1993.
58. Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M, Baggiolini M: Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 155:331-336, 1999.
59. Tekstra J, Beekhuizen H, Van De Gevel JS, Van Benten IJ, Tuk CW, Beelen RH: Infection of human endothelial cells with Staphylococcus aureus induces the production of monocyte chemotactic protein-1 (MCP-1) and monocyte chemotaxis. Clin Exp Immunol 117:489-495, 1999.
60. Capelli A, Di Stefano A, Gnemmi I, Balbo P, Cerutti CG, Balbi B, Lusuardi M, Donner CF: Increased MCP-1 and MIP-1 beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 14:160-165, 1999.
61. Hoch RC, Rodriguez R, Manning T, Bishop M, Mead P, Shoemaker WC, Abraham E: Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med 21:839-845, 1993.
62. Berman JW, Guida MP, Warren J, Amat J, Brosnan CF: Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol 156:3017-3023, 1996.
63. Keel M, Ecknauer E, Stocker R, Ungethum U, Steckholzer U, Kenney J, Gallati H, Trentz O, Ertel W: Different pattern of local and systemic release of proinflammatory and anti-inflammatory mediators in severely injured patients with chest trauma. J Trauma 40:907-912, 1996.
64. Birdsall HH, Green DM, Trial J, Youker KA, Burns AR, MacKay CR, LaRosa GJ, Hawkins HK, Smith CW, Michael LH, Entman ML, Rossen RD: Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 95:684-692, 1997.
65. Ribeiro RA, Souza-Filho MV, Souza MH, Oliveira SH, Costa CH, Cunha FQ, Ferreira HS: Role of resident mast cells and macrophages in the neutrophil migration induced by LTB4, fMLP and C5a des arg. Int Arch Allergy Immunol 112:27-35, 1997.
66. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC: B Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279:381-384, 1998.
67. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA: C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 94:1147-1155, 1994.
68. Noble KE, Panayiotidis P, Collins PW, Hoffbrand AV, Yong KL: Monocytes induce E-selectin gene expression in endothelial cells: role of CD 11/CD18 and extracellular matrix proteins. Eur J Immunol 26:2944-2951, 1996.
69. Melder RJ, Munn LL, Yamada S, Ohkubo C, Jain RK: Selectin- and integrin-mediated T-lymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes. Biophys J 69:2131-2138, 1995.
70. Lim YC, Snapp K, Kansas GS, Camphausen R, Ding H, Luscinskas FW: Important contributions of P-selectin glycoprotein ligand-1-mediated secondary capture to human monocyte adhesion to P-selectin, E-selectin, and TNF-alpha-activated endothelium under flow in vitro. J Immunol 161:2501-2508, 1998.
71. Kuypers TW, Roos D: Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. Res Immunol 140:461-486, 1989.
72. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452, 1992.
73. Beutler B, Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986.
74. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJD, Zentella A, Albert JD, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
75. Tracey KJ, Lowry SF, Cerami A: Cachetin/TNF-alpha in septic shock and septic adult respiratory distress syndrome. Am Rev Respir Dis 138:1377-1379, 1988.
76. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664, 1987.
77. Baumann H, Prowse KR, Marinkovic S, Won KA, Jahreis GP: Stimulation of hepatic acute phase response by cytokines and glucocorticoids. Ann NY Acad Sci 557:280-295, 1989.
78. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC: Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232:347-350, 1988.
79. Meijer C, Huysen V, Smeenk RT, Swaak AJ: Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 2:359-365, 1993.
80. Yamada Y, Kimball K, Okusawa S, Vachino G, Margolis N, Sohn JW, Li JJ, Wakabayashi G, McAdam K, Burke JF, et al.: Cytokines, acute phase proteins, and tissue injury: c-reactive protein opsonizes dead cells for debridement and stimulates cytokine production. Ann NY Acad Sci 587:351-361, 1990.
81. Thiel S, Holmskov U, Hviid L, Laursen SB, Jensenius JC: The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin Exp Immunol 90:31-35, 1992.
82. Thiel S, Petersen SV, Vorup-Jensen T, Matsushita M, Fujita T, Stover CM, Schwaeble WJ, Jensenius JC: Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19. J Immunol 165:878-887, 2000.
83. Fraser IP, Koziel H, Ezekowitz RA: The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 10:363-372, 1998.
84. Movat HZ, Cybulsky MI, Colditz IG, Chan MK, Dinarello CA: Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils. Fed Proc 46:97-104, 1987.
85. Bone RC: Inhibitors of complement and neutrophils: a critical evaluation of their role in the treatment of sepsis. Crit Care Med 20:891-898, 1992.
86. Welbourn CR, Young Y: Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators. Br J Surg 79:998-1003, 1992.
87. Harris MC, Stroobant J, Cody CS, Douglas SD, Polin RA: Phagocytosis of group B streptococcus by neutrophils from newborn infants. Pediatr Res 17: 358-361, 1983.
88. Lanser ME, Saba TM: Opsonic fibronectin is necessary for optimal serum-mediated phagocytosis of Staphylococcus aureus by human neutrophils. Adv Shock Res 8:111-117, 1982.
89. Schorlemmer HU, Hofstaetter T, Seiler FR: Phagocytosis of immune complexes by human neutrophils and monocytes: relative importance of Fc and C3b receptors. Behring Inst Mitt 76:88-97, 1984.
90. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 187:813-818, 1998.
91. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L: Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14:619-648, 1996.
92. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP: Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17:189-220, 1999.
93. Herberman RB, Reynolds CW, Ortaldo JR: Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol 4:651-680, 1986.
94. Li H, Lebedeva MI, Liera AS, Fields BA, Brenner MB, Mariuzza RA: Structure of the Vdelta domain of a human gammadelta T-cell antigen receptor. Nature 391:502-506, 1998.
95. Chien YH, Jores R, Crowley MP: Recognition by gamma/delta T cells. Annu Rev Immunol 14:511-532, 1996.
96. Haas W, Pereira P, Tonegawa S: Gamma/delta cells. Annu Rev Immunol 11:637-685, 1993.
97. Hamann A, Jablonski-Westrich D: Integrins and L-selectin in lymphocyte-endothelium interactions and homing into gut-associated tissue. Behring Inst Mitt 92:30-35, 1993.
98. Huang K, Geoffroy JS, Singer MS, Rosen SD: A lymphocyte homing receptor (L-selectin) mediates the in vitro attachment of lymphocytes to myelinated tracts of the central nervous system. J Clin Invest 88:1778-1783, 1991.
99. Hoag KA, Lipscomb MF, Izzo AA, Street NE: IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol 17:733-739, 1997.
100. Bradley LM, Dalton DK, Croft M: A direct role for IFN-gamma in regulation of Th1 cell development. J Immunol 157:1350-1358, 1996.
101. Stout RD, Bottomly K: Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones: failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. J Immunol 142: 760-765, 1989.
102. Chehimi J, Trinchieri G: Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 14:149-161, 1994.
103. Swain SL, Weinberg AD, English M, Huston G: IL-4 directs the development of Th2-like helper effectors. J Immunol 145:3796-3806, 1990.
104. Tamada K, Harada M, Abe K, Li T, Nomoto K: IL-4-producing NK1.1+ T cells are resistant to glucocorticoid-induced apoptosis: implications for the Th1/Th2 balance. J Immunol 161:1239-1247, 1998.
105. Mosmann TR, Moore KW: The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 12:A49-A53, 1991.
106. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451, 1991.
107. Bendelac A, Rivera MN, Park SH, Roark JH: Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15:535-562, 1997.
108. Brossay L, Burdin N, Tangri S, Kronenberg M: Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands. Immunol Rev 163:139-150, 1998.
109. Vicari AP, Zlotnik A: Mouse NK1.1+ T cells: a new family of T cells. Immunol Today 17:71-76, 1996.
110. Paul WE: Interleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Found Symp 204:208-216, 1997.
111. Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni MP, Rugiu FS, De Carli M, Ricci M, Romagnani S: Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 148:2142-2147, 1992.
112. Morel PA, Oriss TB: Crossregulation between Th1 and Th2 cells. Crit Rev Immunol 18:275-303, 1998.
113. Reed SG: In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. J Immunol 140:4342-4347, 1988.
114. Mackay CR, Marston W, Dudler L: Altered patterns of T cell migration through lymph nodes and skin following antigen challenge. Eur J Immunol 22:2205-2210, 1992.
115. Romanic AM, Graesser D, Baron JL, Visintin I, Janeway CA, Madri JA: T cell adhesion to endothelial cells and extracellular matrix is modulated upon transendothelial cell migration. Lab Invest 76:11-23, 1997.
116. Bradley LM, Watson SR, Swain SL: Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J Exp Med 180:2401-2406, 1994.
117. Chao CC, Jensen R, Dailey MO: Mechanisms of L-selectin regulation by activated T cells. J Immunol 159:1686-1694, 1997.
118. Rigby S, Dailey MO: Traffic of L-selectin-negative T cells to sites of inflammation. Eur J Immunol 30:98-107, 2000.
119. Santamaria LF, Perez Soler MT, Hauser C, Blaser K: Allergen specificity and endothelial transmigration of T cells in allergic contact dermatitis and atopic dermatitis are associated with the cutaneous lymphocyte antigen. Int Arch Allergy Immunol 107:359-362, 1995.
120. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433, 1990.
121. Perez-Perez GI, Cohn DL, Guerrant RL, Patton CM, Reller LB, Blaser MJ: Clinical and immunologic significance of cholera-like toxin and cytotoxin production by Campylobacter species in patients with acute inflammatory diarrhea in the USA. J Infect Dis 160:460-468, 1989.
122. Lonnroth I, Lange S: A new principle for resistance to cholera: desensitization to cyclic AMP-mediated diarrhea induced by cholera toxin in the mouse intestine. J Cyclic Nucleotide Res 7:247-257, 1981.
123. Kaeser HE, Saner A: Tetanus toxin, a neuromuscular blocking agent. Nature 223:842, 1969.
124. Herman A, Kappler JW, Marrack P, Pullen AM: Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu Rev Immunol 9:745-772, 1991.
125. Choi YW, Herman A, DiGiusto D, Wade T, Marrack P, Kappler J: Residues of the variable region of the T-cell-receptor beta-chain that interact with S. aureus toxin superantigens. Nature 346:471-473, 1990.
126. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, Swiss-Dutch J5 Immunoglobulin Study Group: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 161:982-987, 1990.
127. Drost AC, Burleson DG, Cioffi WG, Jordan BS, Mason AD, Pruitt BA: Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. J Trauma 35:335-339, 1993.
128. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993.
129. Neidhardt R, Keel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, Ertel W: Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 42:863-870, 1997.
130. Sherry RM, Cue JI, Goddard JK, Parramore JB, DiPiro JT: Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma 40: 613-617, 1996.
131. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM: High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 145:1016-1022, 1992.
132. Holzheimer RG, Schein M, Wittmann DH: Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Arch Surg 130:1314-1320, 1995.
133. Ksontini R, MacKay SL, Moldawer LL: Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. Arch Surg 133:558-567, 1998.
134. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874, 1992.
135. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128, 1996.
136. Bone RC: Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24:163-172, 1996.
137. Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC: Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 92:11490-11494, 1995.
138. Bengtsson A, Redl H, Paul E, Schlag G, Mollnes TE, Davies J: Complement and leukocyte activation in septic baboons. Circ Shock 39:83-88, 1993.
139. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA: Protective effects of C5a blockade in sepsis. Nat Med 5:788-792, 1999.
140. Friedman G, Jankowski S, Shahla M, Goldman M, Rose RM, Kahn RJ, Vincent JL: Administration of an antibody of E-selectin in patients with septic shock. Crit Care Med 24:229-233, 1996.
141. Cummings CJ, Sessler CN, Beall LD, Fisher BJ, Best AM, Fowler AA: Soluble E-selectin levels in sepsis and critical illness: correlation with infection and hemodynamic dysfunction. Am J Respir Crit Care Med 156:431-437, 1997.
142. Schlag G, Redl HR, Till GO, Davies J, Martin U, Dumont L: Anti-L-selectin antibody treatment of hemorrhagic-traumatic shock in baboons. Crit Care Med 27:1900-1907, 1999.
143. Essani NA, Fisher MA, Simmons CA, Hoover JL, Farhood A, Jaeschke H: Increased P-selectin gene expression in the liver vasculature and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Leukoc Biol 63:288-296, 1998.
144. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552, 1990.
145. Abraham E: Clinical sepsis trials. Chest 105:53S-55S, 1994.
146. Fisher CJ, Opal SM, Lowry SF, Sadoff JC, LaBrecque JF, Donovan HC, Lookabaugh JL, Lemke J, Pribble JP, Stromatt SC, et al.: Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock 44:1-8, 1994.
147. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW: Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:1341-1347, 1995.
148. Hotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman TG, Karl IE: Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med 25:1298-1307, 1997.
149. Cheadle WG, Pemberton RM, Robinson D, Livingston DH, Rodriguez JL, Polk HC Jr: Lymphocyte subset responses to trauma and sepsis. J Trauma 35:844-849, 1993.
150. Menges T, Engel J, Welters I, Wagner RM, Little S, Ruwoldt R, Wollbrueck M, Hempelmann G: Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. Crit Care Med 27:733-740, 1999.
151. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348-351, 1995.
152. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373:438-441, 1995.
153. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, Zollner KM, Buchman TG, Korsmeyer SJ, Karl IE: Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 162:4148-4156, 1999.
154. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE: Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 96:14541-14546, 1999.
155. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I: Immunosuppressive effects of apoptotic cells. Nature 390:350-351, 1997.
156. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, Murphy KM: Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci USA 89: 6065-6069, 1992.
157. Keel M, Ungethum U, Steckholzer U, Niederer E, Hartung T, Trentz O, Ertel W: Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 90:3356-3363, 1997.
158. Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, Marshall JC: Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg 132:1263-1270, 1997.
159. Matute-Bello G, Liles WC, Radella F, 2nd, Steinberg KP, Ruzinski JT, Jonas M, Chi EY, Hudson LD, Martin TR: Neutrophil apoptosis in the acute respiratory distress syndrome. Am J Respir Crit Care Med 156:1969-1977, 1997.
160. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681, 1997.